Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-25
2006-04-25
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C536S023500, C536S024100, C424S093200, C424S093210
Reexamination Certificate
active
07034010
ABSTRACT:
Gene delivery vectors, such as, for example, recombinant FIV vectors, and methods of using such vectors are provided for use in treating or preventing retinal diseases of the eye and diseases of the brain associated with lysosomal storage disorders.
REFERENCES:
patent: 5089392 (1992-02-01), Miller et al.
patent: 5433946 (1995-07-01), Allen, Jr. et al.
patent: 2002/0068354 (2002-06-01), Johnston et al.
patent: WO 97/32983 (1997-09-01), None
patent: WO 98/41644 (1998-09-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/15641 (1999-04-01), None
patent: WO 99/36511 (1999-07-01), None
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, pp. 77-101.
Castro et al., 2001, Histl. Histopathol., vol. 16, pp. 1225-1238.
Ali et al., “Adeno-Associated Virus Gene Transfer to Mouse Retina,”Human Gene Therapy 9:81-86 (1998).
Ali et al., “Gene Transfer into the Mouse Retina Mediated by an Adeno-Associated Viral Vector,”Human Mol. Genet 5:591-594 (1996).
Bennett et al., “Real-Time, Noninvasive In Vivo Assessment of Adeno-Associated Virus-Mediated Retinal Transduction,”Invest Opthalmo Vis Sci 38:2857-2863 (1997).
Borras et al., “Adenoviral Reporter Gene Transfer to the Human Trabecular Meshwork Does Not Alter Aqueous Humor Outlflow. Relevance for Potential Gene Therapy of Glaucoma,”Gene Therapy 6:515-524 (1999).
Bosch et al., “Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene Transfer,”Human Gene Therapy 11:1139-1150 (2000).
Cone and Mulligan, “High Efficiency Gene Transfer into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus With Broad Mammalian Host Range,”Proc. Natl. Acad. Sci. U.S.A. 814:6349 (1984).
Flannery et al., “Efficient Photoreceptor-Targeted Gene Expression In Vivo by Recombinant Adeno-Associated Virus,”Proc. Natl. Acad. Sci. U.S.A. 94:6916-6921 (1997).
Jomary et al., “Rescue of Photoreceptor Function by AAV-Mediated Gene Transfer in a Mouse Model of Inherited Retinal Degeneration,”Gene Therapy 4:683-690 (1997).
Li and Davidson, “Phenotype Correction in Retinal Pigment Epithelium in Murine Mucopolysaccharidosis VII by Adenovirus-Mediated Gene Transfer,”Proc. Natl. Acad, Sci. U.S.A. 92:7700-7704 (1995).
Li et al., “In Vivo Transfer of a Reporter Gene to the Retina Mediated by an Adenoviral Vector,”Inves Optahalmol Vis Sci 35:2543-2549 (1994).
Mann et al., “Construction of a Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus,”Cell 33:153-159 (1983).
Miller et al., “Retrovirus Packaging Cells,”Human Gene Therapy 1:5-14 (1990).
Miyoshi et al., “Stable and Efficient Gene Transfer into the Retina Using an HIV-Based Lentiviral Vector,”Proc. Natl. Acad. Sci. U.S.A. 94:10319-10323 (1997).
Miyoshi et al., “Development of a Self-Inactivating Lentivirus Vector,”Journal of Virology 72(10):8150-8157 (1998).
Ohashi et al., “Adenovirus-Mediated Gene Transfer and Expression of Human β-Glucuronidase Gene in the Liver, Spleen and Central Nervous System in Mucopolysaccharidosis Type VII Mice,”Proc. Natl. Acad. Sci. USA 94:1287-1292 (1997).
Rolling et al., “Evaluation of Adeno-Associated Virus-Mediated Gene Transfer into the Rat Retina by Clinical Fluorescence Photography,”Human Gene Ther 10:641-648 (1999).
Sakamoto et al., “Target Gene Transfer of Tissue Plasminogen Activator to Comea by Electric Pulse Inhibits Intracameral Fibrin Formation and Corneal Cloudiness,”Human Gene Therapy 5:1088-1097 (1999).
Sands et al., “Gene Therapy for Murine Mucopolysaccharidosis Type VII,”Neuromuscular Disorders 7:352-360 (1997).
Takahashi et al., “Rescue from Photoreceptor Degeneration in the rd Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer,”Journal of Virology 73:7812-7816 (1999).
Volgler et al., “Murine Mucopolysaccharidosis Type VII: The Impact of Therapies on the Clinical Course and Pathology in a Murine Model of Lysosomal Storage Disease,”J. Inher. Metab. Dis. 21:575-586 (1998).
Watson et al., “Treatment of Lysosomal Storage Disease in MPS VII Mice using a Recombinant Adeno-Associated Virus,”Gene Therapy 5:1642-1649 (1998).
Eck et al.,Gene-Based Therapy, Goodman & Gilman's, Ninth Ed., pp. 77-101, 1996.
Naffakh et al., “Gene Therapy for Lysosomal Disorders,”Nov Rev. Fr Hematol 36(Suppl. 1):S11-S16 (1994).
Hartung et al., “Enzymatic Correction and Cross-Correction of Mucopolysaccharidosis Type 1 Fibroblasts by Adeno-Associated Virus-Mediated Transduction of the αL-Iduronidase Gene,”Human Gene Therapy 10:2163-2172 (1999).
Hughes et al., “Viral-Mediated Gene Transfer to Mouse Primary Neural Progenitor Cells,”Molecular Therapy 5(1):16-24 (2002).
Takenaka et al., “Circulating α-Galactosidase A Derived from Transduced Bone Marrow Cells: Relevance for Corrective Gene Transfer for Fabry Disease,”Human Gene Therapy 10:1931-1939 (1999).
Davidson Beverly
Dubensky, Jr. Thomas W.
Heth Jason A.
Jolly Douglas J.
Sauter Sybille L.
Chen Shin-Lin
Robins & Pasternak LLP
University of Iowa Research Foundation
LandOfFree
Use of recombinant gene delivery vectors for treating or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of recombinant gene delivery vectors for treating or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of recombinant gene delivery vectors for treating or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554471